SecBot SecBot
SC 13D ·Filed Nov 12, 2026

MTRI

InMed Pharmaceuticals Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed4d 10h ago SEC0001193125-26-458677
Activist investor acquires 5%+ stake
Actionable Insight • Neutral

Fairmount's 19.99% stake and board representation rights give it significant influence over Mentari's strategic direction, particularly regarding migraine prevention therapies. Monitor for any future proposals from Fairmount regarding operational changes, capital allocation, or strategic alternatives.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1
Entry
$18.60
T+0 close · Nov 12, 2026 · via day close
Latest settled
+6.83%
T+1 · $19.87
Vs SPY
+8.74%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $18.60entry
  2. T+1 · 20h ago +6.83%α +8.74% · $19.87
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fairmount Funds Management LLC filed a Schedule 13D disclosing beneficial ownership of 19.99% of Mentari Therapeutics (formerly InMed Pharmaceuticals) common stock, acquired through a reverse merger and PIPE financing. The stake was obtained as part of the merger consideration and a $490M pre-closing financing, with Fairmount holding 10,555,507 shares and additional convertible preferred stock and pre-funded warrants subject to ownership limitations.

Key Financial Metrics

Stake
19.99%
Stake Value
$120.0M
Investor
Fairmount Funds Management LLC

Key Facts

  • Fairmount Funds Management LLC and affiliated entities own 19.99% of Mentari Therapeutics common stock as of November 6, 2026
  • The stake consists of 10,555,507 shares of common stock directly held by Fairmount Healthcare Fund II L.P.
  • Fairmount also holds 4,013 shares of Series A Non-Voting Convertible Preferred Stock convertible into 4,013,000 common shares and 1,468,222 pre-funded warrants, both subject to 19.99% beneficial ownership limitations
  • The aggregate purchase price for the common stock and pre-funded warrants was $119,999,263, plus $200,000 for the Series A Preferred Stock
  • The stake was acquired through the November 6, 2026 reverse merger of InMed Pharmaceuticals with Mentari Therapeutics and a concurrent $490M pre-closing financing
  • Fairmount has the right to elect two directors as long as at least 30% of Series A Preferred Stock remains outstanding
  • Lock-up agreements restrict sale of shares for 180 days after the merger closing

Financial Impact

$120.2 million total investment for 19.99% stake (common + preferred + warrants)

ownershipdilutiongovernance

Risk Factors

  • Fairmount's beneficial ownership limitations (19.99%) may cap future conversion of preferred stock and warrants, limiting potential dilution
  • Lock-up agreements expire 180 days post-merger, potentially leading to selling pressure
  • The filing states no present plans for actions under Item 4, but Fairmount may develop plans in the future

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13D Filing (Primary)0001193125-26-458677
Document: 0001193125-26-458677-index.html0001193125-26-458677
Document: 0001193125-26-458677.txt0001193125-26-458677

US Market Status

Market Closed · Opens in 6h 6m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026